Increase in Travel-Associated and Locally Acquired Dengue Cases — United States, 2024
MMWR. Morbidity and Mortality Weekly Report·
- DOI
- 10.15585/mmwr.mm7518a1
- PMID
- 42133551
- PMCID
- PMC13175395
- OpenAlex
- W7161140647
- Study type
- Journal article
- Publisher
- Centers for Disease Control MMWR Office
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The authors highlight the need for enhanced prevention, clinical awareness, and tailored public health messaging for travelers to dengue-endemic areas, given the marked increase in reported cases and associated hospitalizations and deaths.
Structured evidence summary
Research question
The report characterizes U.S. dengue surveillance data reported through ArboNET for 2024, comparing case counts with prior years and describing case characteristics.
Study design
A descriptive analysis of national surveillance data reported to ArboNET, comparing 2024 case counts against the 2010-2023 annual average.
Population and setting
Persons with dengue reported in the 50 U.S. states and the District of Columbia through ArboNET, including both travel-associated and locally acquired cases, with selected travel destinations identified.
Main findings
A record 3,798 dengue cases were reported in 2024, a 359% increase above the 2010-2023 annual average. Among these, 97.2% were travel-associated and 2.8% were locally acquired. Cases peaked during July-September (41.6%), with the highest proportion (21.8%) in persons aged 50-59 years. Hispanic or Latino persons accounted for 57.5% of cases. Among 1,204 patients with known serotype, DENV-3 was most common (54.8%).
Public-health relevance
The authors highlight the need for enhanced prevention, clinical awareness, and tailored public health messaging for travelers to dengue-endemic areas, given the marked increase in reported cases and associated hospitalizations and deaths.
Important limitations
This summary is limited to the supplied single-article abstract and metadata; the original paper is required for decision-grade interpretation, including review of any explicit limitations of the ArboNET surveillance data analysis.
GIDS interpretation
The article is indexed under dengue, U.S. travel medicine, and surveillance topics, which may aid editorial discoverability; it does not itself confirm or refute any live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.